Promise for a New Targeted Obesity Therapy Soon
August 9, 2019 — New data from Rhythm Pharmaceuticals this week tells us that a new, highly targeted obesity therapy may become available soon. The data come from two phase 3 studies of setmelanotide in rare cases genetic obesity. With these positive results in hand, Rhythm expects to file for FDA approval in late 2019 or early 2020. Thus, […]
